Form 8-K - Current report:
SEC Accession No. 0001683168-25-000537
Filing Date
2025-01-24
Accepted
2025-01-24 17:00:10
Documents
15
Period of Report
2025-01-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT coeptis_8k.htm   iXBRL 8-K 40783
2 FORM OF CONVERTIBLE PROMISSORY NOTE ISSUED TO YA II PN, LTD. coeptis_ex1001.htm EX-10.1 141104
  Complete submission text file 0001683168-25-000537.txt   441731

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE coep-20250117.xsd EX-101.SCH 3263
4 XBRL DEFINITION FILE coep-20250117_def.xml EX-101.DEF 29964
5 XBRL LABEL FILE coep-20250117_lab.xml EX-101.LAB 36481
6 XBRL PRESENTATION FILE coep-20250117_pre.xml EX-101.PRE 26987
17 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5580
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 25554869
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)